華仁藥業(300110.SZ):全資子公司產品胞磷膽鹼鈉氯化鈉注射液、硝酸異山梨酯氯化鈉注射液首次納入國家醫保目錄
格隆匯12月3日丨華仁藥業(300110.SZ)公佈,2021年12月3日,國家醫保局、人力資源社會保障部發布了《關於印發<國家基本醫療保險、工傷保險和生育保險藥品目錄(2021年)>的通知》。公司全資子公司華仁藥業(日照)有限公司產品胞磷膽鹼鈉氯化鈉注射液、全資子公司廣西裕源藥業有限公司產品硝酸異山梨酯氯化鈉注射液首次納入《國家基本醫療保險、工傷保險和生育保險藥品目錄(2021年)》。
胞磷膽鹼鈉氯化鈉注射液主要用於急性顱腦外傷及腦手術後的意識障礙。硝酸異山梨酯氯化鈉注射液主要用於心絞痛和充血性心力衰竭的治療。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.